en · de · es · fr · pt
tb-500-notes.peptides5388.com › Info › Thymosin Beta-4 Fragment Background — 2026 Update

Thymosin Beta-4 Fragment Background — 2026 Update

By Editorial Desk · published 2026-02-03 · last reviewed 2026-02-22 · Info

Everything below concerns lyophilised powder. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.

Updated 2026-02-22. Numbers and descriptions here follow the published literature rather than marketing material.

Thymosin Beta-4 Fragment Background

Discussion of TB-500 appears in several distinct literatures that rarely cite one another. Peer-reviewed studies usually describe in vitro assays or small animal experiments and are cautious about extrapolation. Veterinary and sports communities circulate anecdotal reports with limited methodological detail. Commercial listings add a third layer, often using the name interchangeably with thymosin beta-4 even though the two molecules differ in size and sequence. Regulatory status varies by country, and the compound is not a licensed medicine in most jurisdictions, so readers comparing sources should check which molecule and which purity each source actually describes.

TB-500 is a synthetic seven-residue peptide whose sequence, LKKTETQ, matches the N-terminal actin-binding region of thymosin beta-4. It is usually supplied in an N-terminally acetylated form, a modification that blocks the free amino terminus and can influence behavior in solution. In the research literature the same sequence appears under several names, including thymosin beta-4 fragment and shortened thymosin beta-4. Because it is a short peptide rather than the full 43-residue parent protein, its measured properties differ from those reported for thymosin beta-4 as a whole, and the two are not interchangeable in experimental design.

Thymosin beta-4 itself is a small, widely expressed protein that sequesters monomeric actin and participates in cell migration, angiogenesis, and tissue repair. Researchers have examined the shortened fragment as a possible mimic of some of these activities, reasoning that the actin-binding motif lies within the first few residues. Binding to monomeric actin has been observed in cell-free systems. Whether the fragment reproduces the broader effects of the full protein in living tissue remains an open question, and findings from animal models are frequently cited without a clear bridge to human physiology.

Thymosin Beta-4 Fragment Identity

No major regulatory agency has approved TB-500 for therapeutic use, and it holds no pharmacopoeial monograph. The name appears on the World Anti-Doping Agency prohibited list within the class covering peptide hormones, growth factors, and related substances. Detection in doping control relies on mass spectrometric methods applied to urine, often after preparation steps that concentrate the analyte. Discussion of TB-500 therefore clusters in biochemistry, sports medicine, and anti-doping literature rather than in registered clinical trials.

TB-500 is a synthetic peptide preparation marketed under a name derived from thymosin beta-4, a 43-residue actin-binding protein first isolated from thymus tissue. The full-length protein has a reported molecular mass near 4963 Da, while material sold as TB-500 is often described as a fragment containing the actin-binding motif LKKTETQ. Because suppliers use the name inconsistently, published sources sometimes refer to the same label as a fragment, a synthetic copy, or a related analog. This naming ambiguity complicates direct comparison of reports across studies.

Tb-500 at a glance

PropertyValueNotes
Molecular classSynthetic peptideN-terminal fragment of thymosin beta-4
Residue countSevenSequence LKKTETQ
Approximate mass889 DaAcetylated seven-residue peptide
Common synonymsTB4 fragment, TB500Not identical to full-length TB4
Reported activityActin bindingObserved mainly in cell-free systems

Handling, Storage, and Analysis

Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography together with mass spectrometry. The chromatogram provides a purity estimate as a percentage of total peak area, while the mass spectrum confirms that the observed mass matches the expected value. Amino acid analysis or tandem mass spectrometry sequencing can provide additional confirmation. Reported purity figures depend on the column, gradient, and detection wavelength, so values from different laboratories are not directly comparable without method details.

Lyophilised peptide is normally reconstituted with sterile water or a neutral buffer shortly before use. Because repeated freeze-thaw cycles can degrade the material, dividing a reconstituted solution into single-use aliquots is a common practice. Working solutions are usually kept cold and protected from light. The exact shelf life depends on concentration, buffer composition, and handling, so it is often determined empirically rather than assumed.

Peptide bonds are susceptible to hydrolysis under extreme pH and to enzymatic cleavage if proteases are present. Heat, oxidising agents, and prolonged exposure to light also contribute to loss of material. Aggregation can occur at high concentrations or in certain buffer systems, and it may not be visible to the eye. Storage at -20 C or below is typical for both powder and aliquoted solutions, and desiccation of the powder is preferred.

Related pages on this site

Identification and Molecular Background

Interest in the peptide grew during the 2000s and 2010s, when studies of tendon and ligament injuries in horses reported changes in lesion size after treatment. Those reports circulated widely outside the scientific literature and shaped much of the current online discussion. Subsequent reviews noted inconsistent study design, small groups, and a shortage of independent replication. Popular descriptions often blur the line between the fragment, the complete protein, and unrelated growth factors, which complicates comparisons across sources.

TB-500 is a synthetic peptide whose sequence corresponds to a short fragment near the N-terminus of thymosin beta-4, a small protein present in most mammalian cells. The fragment is commonly cited as containing the actin-binding region of the parent molecule, which is why it appears in laboratory work on cell migration and tissue repair. Suppliers distribute it as a lyophilised powder intended for research use. Its identity is defined by amino acid sequence and by the presence of an acetyl group on the N-terminal residue.

Full-length thymosin beta-4 consists of roughly forty-three amino acids and ranks among the more abundant small proteins in the cytoplasm. The fragment is much shorter, so it cannot reproduce every function attributed to the intact molecule. In cell culture, short actin-binding motifs can interfere with filament dynamics and cell movement, but such observations come from controlled experiments rather than from whole-animal work. Whether a truncated fragment produces the same effects as the parent protein remains an open question.

Notes from published material

=== Modularity === This is the ability of a system or component to operate without reference to its context. The most used standardized DNA parts are BioBrick plasmids, invented by Tom Knight in 2003. Biobricks are stored at the Registry of Standard Biological Parts in Cambridge, Massachusetts. The BioBrick standard has been used by tens of thousands of students worldwide in the international Genetically Engineered Machine (iGEM) competition. BioBrick Assembly Standard 10 promotes modularity by allowing BioBrick coding sequences to be spliced out and exchanged using restriction enzymes EcoRI or XbaI (BioBrick prefix) and SpeI and PstI (BioBrick suffix). Sequence overlap between two genetic elements (genes or coding sequences), called overlapping genes, can prevent their individual manipulation. To increase genome modularity, the practice of genome refactoring or improving "the internal structure of an existing system for future use, while simultaneously maintaining external system function" has been adopted across synthetic biology disciplines. Some notable examples of refactoring including the nitrogen fixation cluster and type III secretion system along with bacteriophages T7 and ΦX174. While DNA is most important for information storage, a large fraction of the cell's activities are carried out by proteins. Tools can send proteins to specific regions of the cell and to link different proteins together.

Plant foods lose less during processing, as they contain pyridoxine, which is more stable than the pyridoxal or pyridoxamine forms found in animal-sourced foods. For example, milk can lose 30–70% of its vitamin B6 content when dried. The vitamin is found in the germ and aleurone layer of grains, so there is more in grains from which these layers have not been removed, for example more in whole wheat bread than in white wheat bread, and more in brown rice than in white rice. Most values shown in the table are rounded to nearest tenth of a milligram:

=== Oath of neutrality === On 15 March 1900, Lord Roberts proclaimed an amnesty for all burghers, except leaders, who took an oath of neutrality and returned quietly to their homes. It is estimated that between 12,000 and 14,000 burghers took this oath between March and June 1900.

=== Femarelle Recharge === Femarelle Recharge is intended for women experiencing common menopausal symptoms such as hot flashes, night sweats, sleep disturbances, and reduced quality of life during menopause. The formulation contains DT56a, flaxseed powder, and vitamin B6.

=== Molar mass of cellulose === In the pulp and paper industry, molar mass is traditionally measured with a method where the intrinsic viscosity (dL/g) of the pulp sample is measured in cupriethylenediamine (Cuen). The intrinsic viscosity [η] is related to the weight-average molar mass (in daltons) by the Mark–Houwink equation: [η] = 0.070 Mw0.70. However, it is typical to cite [η] values directly in dL/g, as the "viscosity" of the cellulose, confusingly as it is not a viscosity.

Sources: en.wikipedia.org

Background from the literature

Treatment of anorexia involves restoring the patient back to a healthy weight, treating their underlying psychological problems, and addressing underlying maladaptive behaviors, often with forms of talking therapy; some examples of clinically proven therapies include cognitive behavioral therapy or Maudsley family therapy, an approach where parents assume responsibility for feeding their child. A daily low dose of olanzapine has been shown to increase appetite and assist with some weight gain in patients. Psychiatrists may prescribe patients with anorexia nervosa forms of medication to better manage anxiety or depression, these being disorders often commonly associated with the disorder. However, medications are not considered a cure for anorexia nervosa: such pathways rather address underlying causes for the disorder, which often assist in recovery of it by allowing the individual to have a clearer and healthier mental state to understand the complications of anorexia nervosa. It does not assist those who do not have any other related mental conditions that affect their ability to do so. It has been proven to assist in the recovery of other eating disorders, such as bulimia nervosa and binge eating disorder. In severe cases, individuals may require to be fed by nasogastric tube to restore weight and healthy nutritional levels by force. Evidence for benefit from nasogastric tube feeding is unclear; some individuals recover after the first incident of admission, while others have recurring treatments over many years: sometimes indefinitely.

=== Agriculture === Similar to other areas, Ningxia has seen a gradual decline of its peasant population due to rural–urban migration. Despite this, the great majority (62.8 percent) was still agricultural at the time of the survey. Animal husbandry is important for the regional economy. In the main pastoral county, Yanchi, it is even the leading industry when specified for the primary sector. The dominant grazing animals are sheep and goat. In the (semi-)pastoral regions, herders engage in a mixed sedentary farming operation of dryland agriculture and extensive animal husbandry, while full nomadic pastoralism is no longer practiced. Since a cattle breeding plan was implemented in 2002, the province has become one of China's main dairy production areas. Ningxia is the principal region of China where wolfberries are grown. Other specialties of Ningxia are licorice, products made from Helan stone, fiddlehead and products made from sheepskin. Ningxia wines are a promising area of development. The Chinese authorities have given approval to the development of the eastern base of the Helan Mountains as an area suitable for wine production. Several large Chinese wine companies including Changyu and Dynasty Wine have begun development in the western region of the province. Together they now own 20,000 acres of land for wine plantations and Dynasty has ploughed 100 million yuan into Ningxia. In addition, the major oil company China Petroleum and Chemical Corporation has founded a grape plantation near the Helan Mountains.

== Works == Tew has co-authored 2 books focusing on carcinogenesis and cancer treatment strategies. He co-wrote Preclinical and Clinical Modulation of Anticancer Drugs with Peter J. Houghton and Janet A. Houghton, providing an analysis of theoretical and practical approaches to the design and implementation of modulation principles. His collaborative work with Gary D. Kruh, Basic Science of Cancer, explored the advancements in cancer research, covering interrelated topics such as tumor suppressor genes, apoptosis, transcriptional regulation, pharmacology of anticancer drugs, cytogenetic techniques, oncogenes, and signal transductions. Tew co-edited books from the series Advances in Cancer Research alongside Paul B. Fisher, where they provided reviews on diverse cancer research topics. In a review published in the Journal of Medicinal Chemistry, Thomas J. Bardos wrote about the series, "This rapidly growing series of volumes containing many excellent, highly informative, in-depth reviews on a variety of timely topics relating to cancer research has always been most representative in the areas of tumor biology and immunology."

== Overview == Generally, it is considered that a hyperbolic structured protein in specific media conditions is ready to do its task, it is active, but some specific deactivation, are responsible for the regulation of some metabolism pathways. Regulatory enzymes are commonly the first enzyme in a multienzyme system: the product of the reaction catalyzed by the first enzyme is the substrate of the second enzyme, so the cell can control the amount of resulting product by regulating the activity of the first enzyme of the pathway. There are many strategies of activation and deactivation of regulatory enzymes. Regulatory enzymes require an extra activation process and need to pass through some modifications in their 3D in order to become functional, for instance, catalyzing enzymes (regulatory enzymes). The regulation of the activation of these catalyzing enzymes is needed in order to regulate the whole reaction speed, so that it is possible to obtain the amount of product required at any time, that makes regulatory enzymes have a biological importance. Therefore, regulatory enzymes, by its controlled activation and are of two types: allosteric enzymes and covalently modulated enzymes; however, an enzyme can combine both types of regulation.

=== Singles === "Life" (1999) "Believer" (1999) "Too Late Tonight" (1999) "Me And My Melody" (2000) "All Will Wait" (2000) "You Are" (2002) "Everlasting Change" (2002) "Life On Mars" (2002) "Let Her Down Easy" (2003) "Words" (2007) "Why Do You Run" (2007) "Come On" (2010) "Broken Dancer" (2010) "The High Life" (2011) "Seven Odd Years" (2012)

Sources: en.wikipedia.org

Further detail

=== Red peppercorns === Red peppercorns usually consist of ripe peppercorn drupes preserved in brine and vinegar. Ripe red peppercorns can also be dried using the same colour-preserving techniques used to produce green pepper.

MS1 is a positive allosteric modulator (PAM) of the μ-opioid receptor (MOR). It was developed from structural modification of the earlier MOR PAM BMS‐986122. The drug has been found to augment the affinity of the MOR agonist levomethadone ((R)-methadone) for the MOR by 7-fold in vitro and to potentiate activation of the MOR by levomethadone by 4-fold in a G protein assay. However, MS1 displays strong probe dependence, and while it potentiates the MOR agonists levomethadone and morphine, it had no effect on the affinity or potency of the MOR agonists DAMGO or endomorphin-1. MS1 shows a preference for β-arrestin recruitment over G protein activation with endomorphin-1 exposure. The drug's actions are reportedly similar to those of BMS-986122, though its unclear if their mechanisms of action are the same. MS1 shows potentiated analgesic effects with opioids in animals. It also did not worsen opioid withdrawal symptoms, respiratory depression, or analgesic tolerance. MS1 and other atypical MOR activators are of potential interest in the development of novel opioid analgesics with reduced adverse effects and misuse potential. MS1 has notably been found to penetrate the blood–brain barrier in animals. The potential of the related MOR PAMs BMS-986121 and BMS-986122 as pharmaceutical drugs has been restricted owing to their complex chemical synthesis. MS1 has a much simpler synthesis in comparison and hence has been regarded as having overcome this limitation. MS1 was first described in the scientific literature by 2015.

== Early life and education == Cameron was born in Champaign, Illinois. The oldest of three brothers, he grew up in the Chicago suburb, Westchester, and graduated in 1975 from Proviso West High School, Hillside, Illinois. Cameron graduated from Duke University (1979) with a B.S.E. in Biomedical Engineering. In May 1979 he joined Advanced Harvesting Systems, a start-up company focused on large-scale plant protein purification, as the first non-founding member of the company. He was married in August 1979 to Sally Jo Clark. Cameron started graduate school at the Massachusetts Institute of Technology in July 1981 and graduated with a Ph.D. in biochemical engineering in December 1986. His Ph.D. advisor was Charles L. Cooney. His Ph.D. thesis was titled “The Production of R-1,2-Propanediol by Clostridium thermosaccharolyticum.”

1983 – 1st Pump MiniMed 502 (Eli Lilly makes synthetic insulin) 1985 – MiniMed 504 Insulin Pump 1992 – Launch Of MiniMed 506 Insulin Pump 1996 – Introduction of MiniMed 507 Pump 1999 – Launch of the Model 507C 1999 – Introduction of MiniMed 508 Insulin Pump 2002 – Inauguration of the MiniMed Paradigm 511 2003 – 1st Wireless MiniMed Paradigm 512/712 (followed by 515/715) 2006 – MiniMed Paradigm REAL-Time 522/722 2010 – MiniMed Paradigm REAL-Time Revel 523/723

== See also == 30mm DS30M Mark 2 Automated Small Calibre Gun British automated mount with 30 mm Bushmaster II Bushmaster III 35/50 mm chain gun Bushmaster IV 40 mm chain gun List of crew-served weapons of the U.S. Armed Forces List of weapons of the United States Marine Corps M230 30 mm automatic cannon Mark 38 25 mm Machine Gun System Bushmaster II 30 mm chain gun Oerlikon KBA 25 mm automatic cannon Shipunov 2A42 30mm automatic cannon

Sources: en.wikipedia.org

Frequently asked questions

Is TB-500 the same as thymosin beta-4?

No. Thymosin beta-4 is a 43-residue protein, while TB-500 refers to a seven-residue fragment corresponding to its N-terminal region. The two names are often used loosely in commercial and community writing, which obscures the difference in size, sequence, and likely behavior.

What activity is attributed to this sequence?

The fragment contains an actin-binding motif, and cell-free experiments show that it can interact with monomeric actin. That observation is the basis for interest in cell migration and repair processes. Effects reported in animals are not established for humans.

Is there a standard purity specification?

Purity is usually stated by the supplier rather than fixed by a pharmacopoeial monograph, and typical listings report a percentage from reverse-phase HPLC. Independent verification is uncommon. Because no single accepted specification exists, comparisons between lots and between suppliers are difficult.

Is TB-500 the same as thymosin beta-4?

Not necessarily. TB-500 is a commercial label that suppliers apply to synthetic peptides described as thymosin beta-4 or a fragment of it. Published research most often studies the full-length protein, so statements about one do not automatically transfer to the other.

Network